21 Antidepressants Compared: Which Work Best for Depression?

Which Antidepressants Work Best for Major Depression?

This is a systematic review and network meta-analysis published in The Lancet, not a single trial: it pools 522 double-blind randomized controlled trials comprising 116,477 adults with unipolar major depressive disorder, and it is an update and expansion of an earlier analysis that covered 12 antidepressants using head-to-head data only. This version compares 21 antidepressants plus placebo for acute treatment. Every antidepressant beat placebo for efficacy, with odds ratios running from 2.13 (95% CrI 1.89 to 2.41) for amitriptyline down to 1.37 (1.16 to 1.63) for reboxetine. For acceptability, measured as dropping out for any reason, only agomelatine (OR 0.84, 95% CrI 0.72 to 0.97) and fluoxetine (0.88, 0.80 to 0.96) had fewer dropouts than placebo, while clomipramine had more (1.30, 1.01 to 1.68).

Dr. Kumar’s Take

This is the study I want any physician prescribing an antidepressant to have read. It replaces marketing claims and prescribing habit with a single pooled evidence base built from double-blind trials, including unpublished data the authors chased down from regulators and manufacturers. I read it as support for informed conversation rather than a leaderboard. The authors themselves rate the certainty of the evidence as moderate to very low, and most of the drug-versus-drug comparisons carry wide credible intervals. My practical reading: all of these drugs work better than placebo, the differences between them are real but modest, and tolerability deserves as much weight in the choice as efficacy does.

Study Snapshot

The authors searched the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, MEDLINE, MEDLINE In-Process, PsycINFO, AMED, PSYNDEX, the UK National Research Register, regulatory agency websites, and international trial registers from inception to January 8, 2016, with no language restrictions. They included double-blind randomized controlled trials of oral monotherapy for the acute treatment of adults aged 18 and older with major depressive disorder diagnosed by standard operationalised criteria. They excluded quasi-randomised trials, incomplete trials, and trials in which 20% or more of participants had bipolar disorder, psychotic depression, or treatment-resistant depression, or had a serious concomitant medical illness. Primary outcomes were efficacy, defined as a reduction of 50% or more on a standardised observer-rated depression scale, and acceptability, defined as discontinuation for any reason. The search returned 28,552 citations. The protocol is registered with PROSPERO, number CRD42012002291.

Concrete Rankings: Most Effective Antidepressants

More effective than other antidepressants in head-to-head studies (range of ORs 1.19 to 1.96):

Agomelatine
Amitriptyline (also the highest efficacy versus placebo, OR 2.13)
Escitalopram
Mirtazapine
Paroxetine
Venlafaxine
Vortioxetine

The study reports these seven as a group. It does not name one of them as the single most effective drug.

Least efficacious in head-to-head studies (range of ORs 0.51 to 0.84):

Fluoxetine (least efficacious group, though among the better tolerated drugs)
Fluvoxamine
Reboxetine (also the lowest efficacy versus placebo, OR 1.37)
Trazodone

Most Tolerable Antidepressants (Lowest Dropout Rates)

Fewer dropouts than placebo:

Agomelatine (OR 0.84, 95% CrI 0.72 to 0.97)
Fluoxetine (OR 0.88, 95% CrI 0.80 to 0.96)

These two were the only antidepressants of the 21 with fewer dropouts than placebo.

More tolerable than other antidepressants in head-to-head studies (range of ORs 0.43 to 0.77):

Agomelatine
Citalopram
Escitalopram
Fluoxetine
Sertraline
Vortioxetine

Highest dropout rates in head-to-head studies (range of ORs 1.30 to 2.32):

Amitriptyline
Clomipramine (also worse than placebo for dropouts, OR 1.30)
Duloxetine
Fluvoxamine
Reboxetine
Trazodone
Venlafaxine

Clinical Decision-Making Framework

Drugs that appear on both favourable lists. Three antidepressants show up among the more effective drugs and among the more tolerable drugs in head-to-head comparisons: agomelatine, escitalopram, and vortioxetine. That overlap is the closest thing this study offers to a balanced starting point, and I treat it that way rather than as a ranking.

If efficacy is the priority. Amitriptyline had the highest efficacy odds ratio against placebo, and it sits in the group with the highest dropout rates. Mirtazapine, paroxetine, and venlafaxine also fall in the more effective head-to-head group, and venlafaxine is in the high-dropout group. The trade-off is explicit in the data.

If tolerability is the priority. Agomelatine and fluoxetine were the only drugs with fewer dropouts than placebo. Citalopram, escitalopram, sertraline, and vortioxetine round out the better tolerated head-to-head group. Fluoxetine sits in the least efficacious head-to-head group at the same time, so tolerability here is bought at some cost in response rate.

Drugs that landed on the unfavourable side of both outcomes. Fluvoxamine, reboxetine, and trazodone appear in the least efficacious head-to-head group and in the highest-dropout group.

Population the framework applies to. These findings cover acute treatment of adults aged 18 and older with major depressive disorder. Trials with substantial proportions of bipolar disorder, psychotic depression, treatment-resistant depression, or serious concomitant medical illness were excluded, so the framework does not speak to those groups.

Safety, Limits, and Caveats

Several limits matter. The analysis covers acute treatment only, so it says nothing about how these drugs perform over the long term, and the authors themselves note that the long-term balance of benefits and harms is often understudied. Of the 522 trials, 46 (9%) were rated high risk of bias, 380 (73%) moderate, and 96 (18%) low, and the certainty of the evidence was moderate to very low. Most of the comparative analyses carry wide credible intervals.

The differences also shrink depending on which trials are counted. When all trials were considered, differences in odds ratios between antidepressants ranged from 1.15 to 1.55 for efficacy and from 0.64 to 0.83 for acceptability. The larger spread appears in head-to-head trials. The analysis used group-level data, so it cannot predict what any one patient will experience, and it excluded treatment-resistant depression, which limits how far the results carry for patients who have already failed several treatments.

Practical Takeaways

All 21 antidepressants beat placebo for response. The question is not whether they work but which one fits a given patient.
Two drugs, agomelatine and fluoxetine, had fewer dropouts than placebo. Clomipramine had more.
Agomelatine, escitalopram, and vortioxetine sit in both the more effective and the more tolerable head-to-head groups. That is a reasonable place to start a conversation about first-line treatment.
Fluvoxamine, reboxetine, and trazodone fall on the unfavourable side of both outcomes. I would want a specific reason before reaching for them.
Expect a trade-off with the most effective drugs. Amitriptyline and venlafaxine are in the more effective group and in the highest-dropout group.
Availability differs by country. Not all 21 of these drugs are marketed everywhere, so check what your prescriber can actually write.
Use the data for shared decision making, not as a verdict. The certainty of evidence is moderate to very low and the credible intervals are wide, so individual response still governs.

Key Study Insights That Change Clinical Practice

The “all antidepressants are equal” idea does not survive intact, but the differences are modest:

Efficacy versus placebo ranges from OR 1.37 (reboxetine) to OR 2.13 (amitriptyline)
Head-to-head comparisons show more variability: ORs of 1.19 to 1.96 for the more effective drugs and 0.51 to 0.84 for the least efficacious
Across all trials, drug-versus-drug differences ranged from 1.15 to 1.55 for efficacy and 0.64 to 0.83 for acceptability
Only 2 of the 21 antidepressants, agomelatine and fluoxetine, were better tolerated than placebo

Specific numbers that matter:

522 trials, 116,477 participants, drawn from 28,552 screened citations
21 antidepressants plus placebo, up from 12 drugs with head-to-head data only in the previous version of this analysis
73% of trials at moderate risk of bias, 9% high and 18% low, with certainty of evidence moderate to very low
Acute treatment endpoint, with response defined as a 50% or greater reduction on a standardised observer-rated scale

Clinical implications:

Start from evidence rather than habit, while treating the rankings as starting points and not as a fixed order
Weigh tolerability alongside efficacy, since the drugs with the strongest efficacy signals often carry the highest dropout rates
Do not dismiss older drugs. Amitriptyline, a tricyclic on the WHO Model List of Essential Medicines, had the highest efficacy odds ratio against placebo
Some drugs underperform on both measures. Fluvoxamine, reboxetine, and trazodone are in the least efficacious and highest-dropout groups

FAQs

What is the single best antidepressant according to this study?

The study does not name one. It reports groups: seven drugs (agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, vortioxetine) were more effective than other antidepressants in head-to-head trials, with ORs of 1.19 to 1.96, and six drugs (agomelatine, citalopram, escitalopram, fluoxetine, sertraline, vortioxetine) were more tolerable, with ORs of 0.43 to 0.77. Amitriptyline had the highest efficacy odds ratio against placebo at 2.13. Agomelatine, escitalopram, and vortioxetine appear on both favourable lists.

Which antidepressants should be avoided?

Fluvoxamine, reboxetine, and trazodone appear in both the least efficacious head-to-head group (ORs 0.51 to 0.84) and the highest-dropout group (ORs 1.30 to 2.32). Reboxetine also had the lowest efficacy against placebo, OR 1.37. Clomipramine had more dropouts than placebo, OR 1.30. I would want a specific clinical reason before choosing any of these.

How should I use these rankings with my doctor?

Bring the outcome you care most about. If response rate matters most, ask about the drugs in the more effective head-to-head group. If side effects have driven you off medication before, ask about the drugs with fewer dropouts, starting with the two that beat placebo on that measure. Asking your prescriber to explain the choice in terms of efficacy and tolerability moves the conversation from opinion to evidence.

Do these results apply if I’ve failed previous antidepressants?

The analysis excluded trials in which 20% or more of participants had treatment-resistant depression. The results can still inform a next choice, but the evidence base behind them was not drawn from patients in that situation.

Why isn’t my doctor using these rankings?

Prescribing habits often predate this analysis, and the study frames itself as evidence to inform shared decision making rather than as a protocol. Raising it at an appointment is a reasonable way to make the reasoning behind a prescription explicit.

Bottom Line

This network meta-analysis of 522 trials and 116,477 participants compared 21 antidepressants for acute treatment of major depressive disorder. All of them were more efficacious than placebo, from OR 1.37 for reboxetine to OR 2.13 for amitriptyline. Only agomelatine (OR 0.84) and fluoxetine (OR 0.88) had fewer dropouts than placebo. Agomelatine, escitalopram, and vortioxetine were in both the more effective and the more tolerable head-to-head groups, while fluvoxamine, reboxetine, and trazodone were on the unfavourable side of both. The differences between active drugs are real but modest, the certainty of evidence is moderate to very low, and the credible intervals are wide, so this is a starting point for an informed conversation rather than a fixed ranking.

Read the complete Lancet study: Comparative efficacy and acceptability of 21 antidepressant drugs